Serum CA 15-3 assay in the diagnosis and follow-up of breast cancer

Kallioniemi, Olli; Oksa, Heikki; Aaran, Ritva-Kaarina; Hietanen, T; Lehtinen, M.; Koivula, Timo

doi:10.1038/bjc.1988.196

Cited by 59 publications

(23 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Appearance of high levels of tumor markers such as CEA and/or CA15.3 found in serum before symptoms of breast cancer appear or metastasis detected physically or radiologically is focus of interest. High levels of tumor markers are usually detected in 40-50% of patients with BC 3-18 months before the radiologic detection of metastasis (Ruibal et al, 1987;Kallioniemi et al, 1988;Safi et al, 1989). In our present study CA15.3 level of the majority of the patients (83.2%) was above the normal range at the time when metastasis was detected using conventional methods and this was consistent with literature.…”

Section: Discussionsupporting

confidence: 81%

Prognostic Significance of Circulating Tumor Cells and Serum CA15-3 Levels in Metastatic Breast Cancer, Single Center Experience, Preliminary Results

Tarhan

Gönel²,

Küçükzeybek³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Breast cancer is the second leading cancer causing death in women. Circulating tumor cells are among the prognostic factors while tumor markers are of diagnostic value and can be used for follow-up. The aim of this study was to investigate the correlation between the prognostic significance of the serum CA15-3 levels, number of circulating tumor cells and histopathological tumor factors. Materials and Methods: Thirty patients recently diagnosed with breast cancer were included in the study. Number of circulating tumor cells and serum CA15-3 level were assessed when metastasis was detected and diagnostic value was assessed. Presence of associations with estrogen and progesterone receptors, c-erbB2, Ki-67 proliferation index and histological grade were also evaluated. Results: Median overall survival of the patients with serum CA15-3 levels of >108 ng/dl was 19 months whereas for those with a low serum level it was 62 months. Median overall survival for CTC ≥5vs CTC<5 patients was 19 months and 40 months respectively. The difference between the two groups was statistically significant. Conclusions: Prognostic significance of the CTC count and CA15-3 levels in metastatic breast cancer patients was demonstrated.

show abstract

Section: Discussionsupporting

confidence: 81%

Prognostic Significance of Circulating Tumor Cells and Serum CA15-3 Levels in Metastatic Breast Cancer, Single Center Experience, Preliminary Results

Tarhan

Gönel²,

Küçükzeybek³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Their use for early detection of metastases seems to be promising (Lamerz et al, 1991;Stieber et al, 1992;Vizcarra et al, 1994;O'Hanlon et al, 1995) and their use for measuring therapeutic response in metastatic disease is widely accepted (Tondini et al, 1988;Dnistrian et al, 1991;Robertson et al, 1991;Safi et al, 1991). Many studies tried to assess the prognostic role of these tumour markers (some analysed in serum, some in tissue), but most of them had low patient numbers or short follow-up periods, and used only univariate analyses (Myers Tormey and Waalkes, 1978;Bezwoda et al, 1981;Mansour et al, 1983;Kallioniemi et al, 1988;Hammer et al, 1992;O'Hanlon et al, 1995). To our knowledge, there is no multivariate analysis on CEA in serum, only a few studies performed multivariate analyses on CEA in breast cancer tissue (Esteban et al, 1994;Sundblad et al, 1996).…”

Section: Discussionmentioning

confidence: 99%

Serum CEA and CA 15-3 as prognostic factors in primary breast cancer

et al. 2002

View full text Add to dashboard Cite

In the present study, we investigated the association of the serum levels of the tumour markers carcinoembryonic antigen and cancer antigen 15-3 with disease free survival and death from disease in 1046 women with breast cancer without metastases at the time of primary diagnosis in relation to age and the established prognostic factors tumour size, lymph node status, histological grading and hormone receptor status. We found that elevated pre-operative serum marker values were correlated with early relapse (cancer antigen 15-3; P=0.0003) and death from disease (carcinoembryonic antigen, cancer antigen 15-3; P=0.0001 both) in univariate analyses. By comparing pre-and post-operative values we found a decline in values post-surgery. In those patients where marker levels of carcinoembryonic antigen decreased more than 33%, a significantly higher risk for relapse and death from disease (both P=0.0001) in univariate analyses was observed. In multivariate analysis this decrease of carcinoembryonic antigen proved to be an independent prognostic factor. The results for cancer antigen 15-3 were comparable to carcinoembryonic antigen in univariate analyses but showed no significance in multivariate analysis. In this study the post-operative decrease of the serum tumour marker carcinoembryonic antigen was a strong independent prognostic factor for disease free survival and death from disease in breast cancer patients.

show abstract

“…The first radioimmunometric assay for CA 15-3 was introduced almost 30 years ago and was based on two monoclonal antibodies: DF3 (raised by mouse immunization using the membrane-enriched fraction of metastatic human breast cancer) (Hayes et al, 1985) and 115D8 (generated after mouse challenge with the membrane of human milk fat globules) (Cheung et al, 2009;Kallioniemi et al, 1988). The most commonly used assays for detecting CA 15-3 are based on sandwich ELISA with 115D8 (used as a capture antibody) and DF3 (as a detecting antibody); these assays are still considered the "gold" standard for breast cancer diagnostics (Klee and Schreiber, 2004).…”

Section: Introductionmentioning

confidence: 99%